Literature DB >> 4400822

Daunorubicin metabolism by human hematological components.

D H Huffman, N R Bachur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4400822

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  7 in total

Review 1.  Mutagenic effects of some anticancer antibiotics.

Authors:  B K Vig
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Influence of tumor on adriamycin concentration in blood cells.

Authors:  M Broggini; T Colombo; S Garattini; M G Donelli
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 3.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

4.  Differential adriamycin distribution to blood components.

Authors:  T Colombo; M Broggini; S Garattini; M G Donelli
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

5.  Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.

Authors:  Federico Pea; Domenico Russo; Mariagrazia Michieli; Daniela Damiani; Renato Fanin; Angela Michelutti; Teresa Michelutti; Stefano Piccolrovazzi; Michele Baccarani; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.

Authors:  B Andersson; M Beran
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: a method analysis.

Authors:  E Kokenberg; P Sonneveld; K Nooter; K van der Steuyt; B Löwenberg
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.